MedTrace Logo

Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue

NCT07561502 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-01

No results posted yet for this study

Summary

This goal of this clinical trial is to determine if the Vanquish System can safely and effectively treat cancerous tissue in the prostate. Researchers will also determine the best treatment dose, monitor safety during and immediately after the procedure, and examine prostate tissue after surgical removal to confirm how well the treatment destroyed targeted tissue. Patients enrolled have been diagnosed with prostate cancer and will undergo treatment with the Vanquish System before their scheduled radical prostatectomy.

Conditions

Interventions

DEVICE

Water Vapor Ablation

Water vapor ablation delivered transurethrally in patients undergoing a radical prostatectomy for prostate cancer.

Sponsors & Collaborators

  • Francis Medical Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-14
Primary Completion
2023-08-11
Completion
2023-08-11

Countries

  • Panama

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07561502 on ClinicalTrials.gov